A Phase I Study of Savolitinib in Patients with Recurrent or Persistent Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

Full Title

A Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

Purpose

The purpose of this study is to find the highest dose of the investigational drug savolitinib that can be given safely in children with certain brain tumors that have come back or continued to grow despite prior treatment. Savolitinib works by blocking the c-MET protein, which some cancers use to grow. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have medulloblastoma, high-grade glioma, or diffuse intrinsic pontine glioma that came back or continues to grow despite prior chemotherapy and/or radiation therapy.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients older than age 5 and no older than 21.

For more information about this study and to inquire about eligibility, please contact Dr. Stephen Gilheeney at 212-639-3973.

Protocol

19-048

Phase

I

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators